Avadel Pharmaceuticals (AVDL) Income towards Parent Company (2016 - 2021)
Historic Income towards Parent Company for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Q4 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' Income towards Parent Company fell 89424.15% to -$23.1 million in Q4 2021 from the same period last year, while for Sep 2022 it was -$23.1 million, marking a year-over-year increase of 6566.75%. This contributed to the annual value of -$85.5 million for FY2021, which is 125357.59% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Income towards Parent Company stood at -$23.1 million for Q4 2021, which was down 89424.15% from -$25.7 million recorded in Q3 2021.
- In the past 5 years, Avadel Pharmaceuticals' Income towards Parent Company registered a high of $30.9 million during Q2 2020, and its lowest value of -$63.9 million during Q4 2018.
- Its 5-year average for Income towards Parent Company is -$9.2 million, with a median of -$11.0 million in 2020.
- Its Income towards Parent Company has fluctuated over the past 5 years, first skyrocketed by 52769.89% in 2017, then plummeted by 89424.15% in 2021.
- Avadel Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$8.2 million in 2017, then plummeted by 674.52% to -$63.9 million in 2018, then increased by 28.68% to -$45.5 million in 2019, then skyrocketed by 94.89% to -$2.3 million in 2020, then crashed by 894.24% to -$23.1 million in 2021.
- Its Income towards Parent Company stands at -$23.1 million for Q4 2021, versus -$25.7 million for Q3 2021 and -$23.3 million for Q2 2021.